Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Convertible Debt (2022 - 2025)

Historic Convertible Debt for ImmunityBio (IBRX) over the last 4 years, with Q3 2025 value amounting to $500.8 million.

  • ImmunityBio's Convertible Debt fell 1482.56% to $500.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $500.8 million, marking a year-over-year decrease of 1482.56%. This contributed to the annual value of $461.9 million for FY2024, which is 1994.52% down from last year.
  • As of Q3 2025, ImmunityBio's Convertible Debt stood at $500.8 million, which was down 1482.56% from $492.1 million recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Convertible Debt ranged from a high of $588.0 million in Q3 2024 and a low of $165.3 million during Q3 2023
  • Over the past 4 years, ImmunityBio's median Convertible Debt value was $492.1 million (recorded in 2025), while the average stood at $447.9 million.
  • Within the past 5 years, the most significant YoY rise in ImmunityBio's Convertible Debt was 25572.54% (2024), while the steepest drop was 1994.52% (2024).
  • Over the past 4 years, ImmunityBio's Convertible Debt (Quarter) stood at $241.3 million in 2022, then surged by 139.13% to $577.0 million in 2023, then decreased by 19.95% to $461.9 million in 2024, then increased by 8.43% to $500.8 million in 2025.
  • Its Convertible Debt stands at $500.8 million for Q3 2025, versus $492.1 million for Q2 2025 and $485.7 million for Q1 2025.